These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

253 related items for PubMed ID: 21540861

  • 1. Vatalanib for metastatic gastrointestinal stromal tumour (GIST) resistant to imatinib: final results of a phase II study.
    Joensuu H, De Braud F, Grignagni G, De Pas T, Spitalieri G, Coco P, Spreafico C, Boselli S, Toffalorio F, Bono P, Jalava T, Kappeler C, Aglietta M, Laurent D, Casali PG.
    Br J Cancer; 2011 May 24; 104(11):1686-90. PubMed ID: 21540861
    [Abstract] [Full Text] [Related]

  • 2. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate.
    Joensuu H, De Braud F, Coco P, De Pas T, Putzu C, Spreafico C, Bono P, Bosselli S, Jalava T, Laurent D, Casali PG.
    Ann Oncol; 2008 Jan 24; 19(1):173-7. PubMed ID: 17698976
    [Abstract] [Full Text] [Related]

  • 3. [Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
    Italiano A, Bui B.
    Bull Cancer; 2008 Jan 24; 95(1):107-16. PubMed ID: 18230576
    [Abstract] [Full Text] [Related]

  • 4. Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial.
    Adenis A, Blay JY, Bui-Nguyen B, Bouché O, Bertucci F, Isambert N, Bompas E, Chaigneau L, Domont J, Ray-Coquard I, Blésius A, Van Tine BA, Bulusu VR, Dubreuil P, Mansfield CD, Acin Y, Moussy A, Hermine O, Le Cesne A.
    Ann Oncol; 2014 Sep 24; 25(9):1762-1769. PubMed ID: 25122671
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
    Demetri GD, Reichardt P, Kang YK, Blay JY, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Schöffski P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG, GRID study investigators.
    Lancet; 2013 Jan 26; 381(9863):295-302. PubMed ID: 23177515
    [Abstract] [Full Text] [Related]

  • 6. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.
    Wu L, Zhang Z, Yao H, Liu K, Wen Y, Xiong L.
    Drug Des Devel Ther; 2014 Jan 26; 8():2061-7. PubMed ID: 25378911
    [Abstract] [Full Text] [Related]

  • 7. Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib.
    Janeway KA, Albritton KH, Van Den Abbeele AD, D'Amato GZ, Pedrazzoli P, Siena S, Picus J, Butrynski JE, Schlemmer M, Heinrich MC, Demetri GD.
    Pediatr Blood Cancer; 2009 Jul 26; 52(7):767-71. PubMed ID: 19326424
    [Abstract] [Full Text] [Related]

  • 8. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
    Heinrich MC, Maki RG, Corless CL, Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB, Fletcher JA, Fletcher CD, Huang X, Cohen DP, Baum CM, Demetri GD.
    J Clin Oncol; 2008 Nov 20; 26(33):5352-9. PubMed ID: 18955458
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.
    George S, Wang Q, Heinrich MC, Corless CL, Zhu M, Butrynski JE, Morgan JA, Wagner AJ, Choy E, Tap WD, Yap JT, Van den Abbeele AD, Manola JB, Solomon SM, Fletcher JA, von Mehren M, Demetri GD.
    J Clin Oncol; 2012 Jul 01; 30(19):2401-7. PubMed ID: 22614970
    [Abstract] [Full Text] [Related]

  • 10. The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.
    Rutkowski P, Bylina E, Klimczak A, Switaj T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz W, Osuch C, Mierzejewska E, Wasielewski K, Woźniak A, Grzesiakowska U, Nowecki ZI, Siedlecki JA, Limon J.
    BMC Cancer; 2012 Mar 22; 12():107. PubMed ID: 22439647
    [Abstract] [Full Text] [Related]

  • 11. Medical treatment of gastrointestinal stromal tumors: state of the art and future perspectives.
    Apice G, Milano A, Bruni GS, Iaffaioli RV, Caponigro F.
    Rev Recent Clin Trials; 2006 Jan 22; 1(1):35-42. PubMed ID: 18393778
    [Abstract] [Full Text] [Related]

  • 12. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P, Blay JY, Gelderblom H, Schlemmer M, Demetri GD, Bui-Nguyen B, McArthur GA, Yazji S, Hsu Y, Galetic I, Rutkowski P.
    Ann Oncol; 2012 Jul 22; 23(7):1680-7. PubMed ID: 22357255
    [Abstract] [Full Text] [Related]

  • 13. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T, Omori T, Ueshima S.
    Gan To Kagaku Ryoho; 2011 May 22; 38(5):733-7. PubMed ID: 21566432
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of sunitinib in Chinese patients with imatinib-resistant or -intolerant gastrointestinal stromal tumors.
    Li J, Gao J, Hong J, Shen L.
    Future Oncol; 2012 May 22; 8(5):617-24. PubMed ID: 22646775
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
    Demetri GD, van Oosterom AT, Garrett CR, Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher CD, George S, Bello CL, Huang X, Baum CM, Casali PG.
    Lancet; 2006 Oct 14; 368(9544):1329-38. PubMed ID: 17046465
    [Abstract] [Full Text] [Related]

  • 16. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib.
    Shinagare AB, Jagannathan JP, Kurra V, Urban T, Manola J, Choy E, Demetri GD, George S, Ramaiya NH.
    Eur J Cancer; 2014 Mar 14; 50(5):981-6. PubMed ID: 24388774
    [Abstract] [Full Text] [Related]

  • 17. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
    George S, Blay JY, Casali PG, Le Cesne A, Stephenson P, Deprimo SE, Harmon CS, Law CN, Morgan JA, Ray-Coquard I, Tassell V, Cohen DP, Demetri GD.
    Eur J Cancer; 2009 Jul 14; 45(11):1959-68. PubMed ID: 19282169
    [Abstract] [Full Text] [Related]

  • 18. Phase I/II study of sunitinib malate in Japanese patients with gastrointestinal stromal tumor after failure of prior treatment with imatinib mesylate.
    Shirao K, Nishida T, Doi T, Komatsu Y, Muro K, Li Y, Ueda E, Ohtsu A.
    Invest New Drugs; 2010 Dec 14; 28(6):866-75. PubMed ID: 19730791
    [Abstract] [Full Text] [Related]

  • 19. Nilotinib in patients with GIST who failed imatinib and sunitinib: importance of prior surgery on drug bioavailability.
    Kim KP, Ryu MH, Yoo C, Ryoo BY, Choi DR, Chang HM, Lee JL, Beck MY, Kim TW, Kang YK.
    Cancer Chemother Pharmacol; 2011 Aug 14; 68(2):285-91. PubMed ID: 20957481
    [Abstract] [Full Text] [Related]

  • 20. [Efficacy and safety of sunitinib on patients with imatinib-resistant gastrointestinal stromal tumor].
    Liu X, Jiang WZ, Guan GX, Chen ZF, Chi P, Lu HS.
    Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar 14; 16(3):221-5. PubMed ID: 23536339
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.